Given that adipose tissue dysfunction contributes to MASLD by promoting lipolysis, increasing FFA flux to the liver, and releasing pro-inflammatory adipokines such as TNF-α, IL-6, and leptin [48], these changes imply that Wv2365 may exert beneficial regulatory effects on the liver–adipose tissue axis. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.